Details

Autor(en) / Beteiligte

• Wen, Wan-Hsin
• Chen, Huey-Ling
• Shih, Tiffany Ting-Fang
• Wu, Jia-Feng
• Ni, Yen-Hsuan
• Lee, Chien-Nan
• Zhao, Lu-Lu
• Lai, Ming-Wei
• Mu, Shu-Chi
• Tung, Yi-Ching
• Hsu, Hong-Yuan
• Chang, Mei-Hwei
• Shyu, M.K.
• Hwa, H.L.
• Su, Y.N.
• Shih, J.C.
• Chao, K.H.
• Chiu, Y.C.
• Chang, K.C.
• Liu, C.J.
• Su, T.H.
• Chen, D.S.
• Chen, S.M.
• Lin, C.C.
• Lin, P.Y.
• Yang, W.R.
• Hu, J.J.
• Yang, C.K.
• Chang, Y.K.
• Chen, K.H.
• Lin, H.H.
• Lin, Y.H.
• Chen, H.J.
• Pan, H.S.
• Lau, B.H.
• Lee, C.L.
• Cheng, P.J.
• Chang, Y.L.
• Chiueh, H.Y.
• Wang, T.H.
• Hsu, J.J.
• Lo, L.M.
• Hsieh, C.L.
• Cheng, S.W.
• Tsai, M.S.
• Lin, L.H.
• She, B.Q.
• Peng, F.S.
• Lin, Y.C.
• Chen, C.P.
• Huang, J.P.
• Yeung, C.Y.

Titel

Long-term growth and bone development in children of HBV-infected mothers with and without fetal exposure to tenofovir disoproxil fumarate

Ist Teil von

• Journal of hepatology, 2020-06, Vol.72 (6), p.1082-1087

Ort / Verlag

Netherlands: Elsevier B.V

Erscheinungsjahr

2020

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Tenofovir disoproxil fumarate (TDF) is the preferred treatment to prevent maternal transmission of HBV, owing to its efficacy and safety. However, data are lacking on the long-term safety outcomes in children following fetal exposure to TDF. Children participating in a prospective, multisite trial of maternal TDF treatment during late pregnancy were recruited for follow-up visits once a year. Growth parameters, serum biochemistry, HBV serology, and bone mineral density (BMD) by dual-energy x-ray absorptiometery scan were measured. One hundred and twenty-eight children, 71 in the TDF and 57 in the control group, completed 255 follow-up visits at the age of 2 to 7 (median, 4.08) years. No differences in z-scores for weight-for-age (0.26 ± 0.90 vs. 0.22 ± 0.99, p = 0.481), z-scores for height-for-age (0.20 ± 1.02 vs. 0.25 ± 0.98, p = 0.812), and estimated glomerular filtration rate (169.12 ± 50.48 vs. 169.06 ± 34.46 ml/min/1.73m2, p = 0.479) were detected. After adjustment for age, sex and HBV status by multiple linear regression, children in the TDF and control group had comparable levels of serum calcium, phosphorus, bone-specific alkaline phosphatase, calcidiol and BMD of lumbar spines (0.55 ± 0.01 vs. 0.57 ± 0.01 g/cm2, p = 0.159) and left hip (0.56 ± 0.01 vs. 0.56 ± 0.01 g/cm2, p = 0.926). Children of HBV-infected mothers who did or did not receive tenofovir disoproxil fumarate treatment during late pregnancy had comparable long-term growth, renal function, and bone development up to 6–7 years after delivery. NCT01312012 (ClinicalTrials.gov) Currently there are insufficient long-term safety data in children born to mothers who took antiviral agents during pregnancy to prevent mother-to-infant transmission of hepatitis B virus (HBV). In this study, we found that children of HBV-infected mothers who did or did not receive tenofovir disoproxil fumarate treatment during late pregnancy had comparable long-term growth, renal function, and bone development up to 6-7 years after delivery. [Display omitted] •Short-term TDF use during pregnancy to prevent maternal HBV transmission is safe.•Children with and without fetal exposure to TDF have comparable long-term growth.•Children's renal function and bone development are unaffected.